Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension.
- Author:
Ping-xian YE
1
;
Ping-zhen YE
1
;
Jian-hua ZHU
2
;
Wei CHEN
1
;
Dan-chen GAO
2
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Atorvastatin Calcium; C-Reactive Protein; metabolism; Double-Blind Method; Endothelins; blood; Exercise Tolerance; drug effects; Female; Heart Failure; complications; drug therapy; physiopathology; Heptanoic Acids; pharmacology; Humans; Hypertension; complications; drug therapy; physiopathology; Male; Middle Aged; Natriuretic Peptide, Brain; blood; Prospective Studies; Pyrroles; pharmacology
- From: Journal of Zhejiang University. Medical sciences 2014;43(3):298-304
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension.
METHODSA randomized, double-blind, placebo-controlled prospective study was performed. Sixty patients with diastolic dysfunction (mitral flow velocity E/A <1) and exercise-induced hypertension (SBP>200 mm Hg) treated with atorvastatin (20 mg q.d) or placebo for 1 year. Cardiopulmonary exercise test and exercise blood pressure measurement were performed. Plasma B-natriuretic peptide (BNP) concentration at rest and at peak exercise, plasma high sensitive-C reaction protein (hs-CRP) and endothelin (ET) concentration were determined at baseline and after treatment.
RESULTSAfter treatment by atorvastatin, the resting SBP, pulse pressure, the peak exercise SBP and BNP were significantly decreased; and the exercise time, metabolic equivalent, maximal oxygen uptake and anaerobic threshold were increased. All of these parameters had significant differences with baseline levels (P<0.05) and the rest pulse pressure, the peak exercise SBP and BNP, and the exercise time had significant differences compared with placebo treatment (P<0.05). Plasma concentrations of hs-CRP and ET were markedly reduced by atorvastatin treatment compared with baseline and placebo (P<0.05). No difference in above parameters was found before and after placebo treatment (P>0.05).
CONCLUSIONIn patients with diastolic dysfunction at rest and exercise-induced hypertension, atorvastatin can effectively reduce plasma hs-CRP and ET level, lower blood pressure and peak exercise SBP, decrease peak exercise plasma BNP concentration, and ultimately improve exercise tolerance.